Generic-drug manufacturer BioComp is offering covered entities refunds for lower 340B prices that it did not pay on six NDCs for periods over eight years, starting in Q3 2013 and ending in Q2 2021.
BioComp, a wholly-owned subsidiary of San Antonio, TX-based Mission Pharmacal, announced the refunds on the U.S. Health Resources and Services Administration (HRSA) website last week. HRSA audited BioComp during fiscal 2021. The published audit findings said the company “did not offer covered outpatient drugs to eligible covered entities at the statutory ceiling price.”
Generic-drug manufacturer BioComp is offering covered entities refunds for lower 340B prices that it did not pay on six NDCs for periods over eight years, starting in Q3 2013 and ending in Q2 2021.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.